The impact of mycophenolate mofetil on long-term outcomes in kidney transplantation

Titte R. Srinivas, Bruce Kaplan, Jesse D. Schold, Herwig Ulf Meier-Kriesche

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Mycophenolate mofetil (MMF) has been used in kidney and pancreas transplantation for almost 10 years. In the pivotal phase III trials, MMF use was accompanied by a dramatic reduction of rejection rates in kidney transplantation; however, the impact on graft and patient was undetermined. Analyses of the United States Renal Data System and the Scientific Registry of Transplant Recipients databases later provided a valuable measure of the impact of MMF in improving outcomes. In this review, we provide a synopsis of the prospective studies, including but not limited to the pivotal MMF approval trials, and analyses of the national transplant registries relevant to the long-term impact of MMF in kidney transplantation. Indeed, a substantial body of evidence has shown MMF treatment improves patient survival, graft survival, and death-censored graft survival in kidney transplantation. The beneficial effects of MMF have been particularly notable in high-risk recipients such as African Americans. In coming years, these benefits will require reevaluation in the context of the growing use of novel protocols combining MMF with tacrolimus or sirolimus.

Original languageEnglish (US)
JournalTransplantation
Volume80
Issue numberSUPPL. 2
DOIs
StatePublished - Oct 15 2005
Externally publishedYes

Fingerprint

Mycophenolic Acid
Kidney Transplantation
Graft Survival
Registries
Transplants
Pancreas Transplantation
Tacrolimus
Sirolimus
Information Systems
African Americans
Databases
Prospective Studies
Kidney
Survival

Keywords

  • African Americans
  • Calcineurin inhibitors
  • Kidney transplantation
  • Mycophenolate mofetil
  • Sirolimus

ASJC Scopus subject areas

  • Transplantation
  • Immunology

Cite this

The impact of mycophenolate mofetil on long-term outcomes in kidney transplantation. / Srinivas, Titte R.; Kaplan, Bruce; Schold, Jesse D.; Meier-Kriesche, Herwig Ulf.

In: Transplantation, Vol. 80, No. SUPPL. 2, 15.10.2005.

Research output: Contribution to journalArticle

Srinivas, Titte R. ; Kaplan, Bruce ; Schold, Jesse D. ; Meier-Kriesche, Herwig Ulf. / The impact of mycophenolate mofetil on long-term outcomes in kidney transplantation. In: Transplantation. 2005 ; Vol. 80, No. SUPPL. 2.
@article{d6e345451350494da78e3a56b80b352e,
title = "The impact of mycophenolate mofetil on long-term outcomes in kidney transplantation",
abstract = "Mycophenolate mofetil (MMF) has been used in kidney and pancreas transplantation for almost 10 years. In the pivotal phase III trials, MMF use was accompanied by a dramatic reduction of rejection rates in kidney transplantation; however, the impact on graft and patient was undetermined. Analyses of the United States Renal Data System and the Scientific Registry of Transplant Recipients databases later provided a valuable measure of the impact of MMF in improving outcomes. In this review, we provide a synopsis of the prospective studies, including but not limited to the pivotal MMF approval trials, and analyses of the national transplant registries relevant to the long-term impact of MMF in kidney transplantation. Indeed, a substantial body of evidence has shown MMF treatment improves patient survival, graft survival, and death-censored graft survival in kidney transplantation. The beneficial effects of MMF have been particularly notable in high-risk recipients such as African Americans. In coming years, these benefits will require reevaluation in the context of the growing use of novel protocols combining MMF with tacrolimus or sirolimus.",
keywords = "African Americans, Calcineurin inhibitors, Kidney transplantation, Mycophenolate mofetil, Sirolimus",
author = "Srinivas, {Titte R.} and Bruce Kaplan and Schold, {Jesse D.} and Meier-Kriesche, {Herwig Ulf}",
year = "2005",
month = "10",
day = "15",
doi = "10.1097/01.tp.0000186379.15301.e5",
language = "English (US)",
volume = "80",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",
number = "SUPPL. 2",

}

TY - JOUR

T1 - The impact of mycophenolate mofetil on long-term outcomes in kidney transplantation

AU - Srinivas, Titte R.

AU - Kaplan, Bruce

AU - Schold, Jesse D.

AU - Meier-Kriesche, Herwig Ulf

PY - 2005/10/15

Y1 - 2005/10/15

N2 - Mycophenolate mofetil (MMF) has been used in kidney and pancreas transplantation for almost 10 years. In the pivotal phase III trials, MMF use was accompanied by a dramatic reduction of rejection rates in kidney transplantation; however, the impact on graft and patient was undetermined. Analyses of the United States Renal Data System and the Scientific Registry of Transplant Recipients databases later provided a valuable measure of the impact of MMF in improving outcomes. In this review, we provide a synopsis of the prospective studies, including but not limited to the pivotal MMF approval trials, and analyses of the national transplant registries relevant to the long-term impact of MMF in kidney transplantation. Indeed, a substantial body of evidence has shown MMF treatment improves patient survival, graft survival, and death-censored graft survival in kidney transplantation. The beneficial effects of MMF have been particularly notable in high-risk recipients such as African Americans. In coming years, these benefits will require reevaluation in the context of the growing use of novel protocols combining MMF with tacrolimus or sirolimus.

AB - Mycophenolate mofetil (MMF) has been used in kidney and pancreas transplantation for almost 10 years. In the pivotal phase III trials, MMF use was accompanied by a dramatic reduction of rejection rates in kidney transplantation; however, the impact on graft and patient was undetermined. Analyses of the United States Renal Data System and the Scientific Registry of Transplant Recipients databases later provided a valuable measure of the impact of MMF in improving outcomes. In this review, we provide a synopsis of the prospective studies, including but not limited to the pivotal MMF approval trials, and analyses of the national transplant registries relevant to the long-term impact of MMF in kidney transplantation. Indeed, a substantial body of evidence has shown MMF treatment improves patient survival, graft survival, and death-censored graft survival in kidney transplantation. The beneficial effects of MMF have been particularly notable in high-risk recipients such as African Americans. In coming years, these benefits will require reevaluation in the context of the growing use of novel protocols combining MMF with tacrolimus or sirolimus.

KW - African Americans

KW - Calcineurin inhibitors

KW - Kidney transplantation

KW - Mycophenolate mofetil

KW - Sirolimus

UR - http://www.scopus.com/inward/record.url?scp=27644540081&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27644540081&partnerID=8YFLogxK

U2 - 10.1097/01.tp.0000186379.15301.e5

DO - 10.1097/01.tp.0000186379.15301.e5

M3 - Article

C2 - 16251854

AN - SCOPUS:27644540081

VL - 80

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - SUPPL. 2

ER -